/Investor DB

Gurnet Point Capital — Full Portfolio

4 tracked investments · listed companies and verified rows first

Macrolide PharmaceuticalsinApr 2018 · $20M

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)Henry Skinner(Director)inVikas Goyal(Director)Raj Parekh(Director)in

Co-investorsAdvent Life SciencesNovartis Venture FundRoche Venture Fund

Naverisnaveris.comin𝕏Sep 2022 · $51M

Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers.

BiotechData & InfrastructureDigital HealthHealthtechMedical DevicesWaltham, US

James McNally(Executive Officer, Director)inPiyush Gupta(Executive Officer, Director)

BoardAnne Stone(Director)Francis Crispino(Director)Philip Grahame Haydon(Director)

Co-investorsBrightEdgeTechU Ventures

Tremeau Pharmaceuticalstremeau.cominOct 2016

Tremeau develops non-opioid pain therapies for patient populations with high unmet medical needs.

BiotechHealthtechCambridge, US

Bradford C. Sippy(Executive Officer, Director)Benjamin Enerson(Executive Officer)Mark Corrigan(Executive Officer)in

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Innocoll Holdings

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.